Raras
Buscar doenças, sintomas, genes...
Disautonomia familiar
ORPHA:1764CID-10 · G90.1CID-11 · 8C21.1OMIM 223900DOENÇA RARA

Uma doença de nascença causada por alterações no gene IKBKAP. Ela se caracteriza por afetar as partes do sistema nervoso que controlam funções automáticas do corpo, como a digestão e os batimentos cardíacos, e também as partes responsáveis pela sensibilidade, como o tato e a percepção de dor.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Uma doença de nascença causada por alterações no gene IKBKAP. Ela se caracteriza por afetar as partes do sistema nervoso que controlam funções automáticas do corpo, como a digestão e os batimentos cardíacos, e também as partes responsáveis pela sensibilidade, como o tato e a percepção de dor.

Pesquisas ativas
3 ensaios
14 total registrados no ClinicalTrials.gov
Publicações científicas
691 artigos
Último publicado: 2026 Apr 10
Medicamentos
2 registrados
CARBIDOPA, CARBIDOPA ANHYDROUS

Tem tratamento?

2 medicamentos registrados
Ver detalhes, fases e interações →
CARBIDOPACARBIDOPA ANHYDROUS

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
<1 / 1 000 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Europe
Início
Childhood
+ infancy, neonatal
🏥
SUS: Cobertura mínimaScore: 15%
CID-10: G90.1
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (2)
0202010694
Sequenciamento completo do exoma (WES)genetic_test
0301070040
Atendimento em reabilitação — doenças rarasrehabilitation
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

👁️
Olhos
9 sintomas
🧠
Neurológico
7 sintomas
🫘
Rins
6 sintomas
🫃
Digestivo
4 sintomas
🦴
Ossos e articulações
3 sintomas
📏
Crescimento
2 sintomas

+ 25 sintomas em outras categorias

Características mais comuns

90%prev.
Sensação de dor prejudicada
Muito frequente (99-80%)
90%prev.
Neuropatia periférica
Muito frequente (99-80%)
90%prev.
Dificuldades alimentares na infância
Muito frequente (99-80%)
90%prev.
Anormalidade no EMG
Muito frequente (99-80%)
90%prev.
Hipo-hidrose
Muito frequente (99-80%)
90%prev.
Hipotensão ortostática
Muito frequente (99-80%)
61sintomas
Muito frequente (12)
Frequente (8)
Ocasional (17)
Sem dados (24)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 61 características clínicas mais associadas, ordenadas por frequência.

Sensação de dor prejudicadaImpaired pain sensation
Muito frequente (99-80%)90%
Neuropatia periféricaPeripheral neuropathy
Muito frequente (99-80%)90%
Dificuldades alimentares na infânciaFeeding difficulties in infancy
Muito frequente (99-80%)90%
Anormalidade no EMGEMG abnormality
Muito frequente (99-80%)90%
Hipo-hidroseHypohidrosis
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2025
Total histórico691PubMed
Últimos 10 anos181publicações
Pico201623 papers
Linha do tempo
2025Hoje · 2026🧪 2009Primeiro ensaio clínico📈 2016Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição. Padrão de herança: Autosomal recessive.

ELP1Elongator complex protein 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the elongator complex which is required for multiple tRNA modifications, including mcm5U (5-methoxycarbonylmethyl uridine), mcm5s2U (5-methoxycarbonylmethyl-2-thiouridine), and ncm5U (5-carbamoylmethyl uridine) (PubMed:29332244). The elongator complex catalyzes the formation of carboxymethyluridine in the wobble base at position 34 in tRNAs (PubMed:29332244). Regulates the migration and branching of projection neurons in the developing cerebral cortex, through a process depending on

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (1)
HATs acetylate histones
MECANISMO DE DOENÇA

Neuropathy, hereditary sensory and autonomic, 3

A form of hereditary sensory and autonomic neuropathy, a genetically and clinically heterogeneous group of disorders characterized by degeneration of dorsal root and autonomic ganglion cells, and by sensory and/or autonomic abnormalities. HSAN3 patients manifest a variety of symptoms such as alacrima, decreased taste, decreased sensitivity to pain and temperature, vasomotor instability, hypoactive or absent deep tendon reflexes, vomiting crises, and gastrointestinal dysfunction.

VIAS REACTOME (1)
OUTRAS DOENÇAS (2)
Riley-Day syndromemedulloblastoma
HGNC:5959UniProt:O95163

Medicamentos e terapias

CARBIDOPAPhase 2

Mecanismo: DOPA decarboxylase inhibitor

CARBIDOPA ANHYDROUSPhase 2

Mecanismo: DOPA decarboxylase inhibitor

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

471 variantes patogênicas registradas no ClinVar.

🧬 ELP1: NM_003640.5(ELP1):c.2366A>G (p.Glu789Gly) ()
🧬 ELP1: NM_003640.5(ELP1):c.3266G>A (p.Trp1089Ter) ()
🧬 ELP1: NM_003640.5(ELP1):c.1528G>T (p.Glu510Ter) ()
🧬 ELP1: NM_003640.5(ELP1):c.2042_2043del (p.His681fs) ()
🧬 ELP1: NM_003640.5(ELP1):c.2128C>T (p.Gln710Ter) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 1,046 variantes classificadas pelo ClinVar.

105
941
Patogênica (10.0%)
VUS (90.0%)
VARIANTES MAIS SIGNIFICATIVAS
ELP1: NM_003640.5(ELP1):c.3802del (p.Arg1268fs) [Pathogenic]
ELP1: NM_003640.5(ELP1):c.8_9del (p.Asn3fs) [Pathogenic]
ELP1: NM_003640.5(ELP1):c.3932-578C>T [Uncertain significance]
ELP1: NM_003640.5(ELP1):c.304-583C>T [Uncertain significance]
ELP1: NM_003640.5(ELP1):c.2588-3T>G [Uncertain significance]

Vias biológicas (Reactome)

1 via biológica associada aos genes desta condição.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 32
2Fase 27
1Fase 11
·Pré-clínico4
Medicamentos catalogadosEnsaios clínicos· 2 medicamentos · 12 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Disautonomia familiar

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

2 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

14 ensaios clínicos encontrados, 3 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
172 papers (10 anos)
#1

AAV2-mediated intravitreal delivery of exon-specific U1 snRNA rescues optic neuropathy in familial dysautonomia.

Molecular therapy. Nucleic acids2026 Mar 12

Familial dysautonomia (FD) is a rare autosomal recessive neurodegenerative disorder caused by a splicing mutation in the ELP1 gene. It predominantly affects the sensory and autonomic nervous systems, with progressive vision loss due to optic neuropathy being a universal and debilitating symptom. Retinal pathology in FD involves progressive thinning of the retinal nerve fiber layer (RNFL), resulting from the degeneration of retinal ganglion cells (RGCs). Notably, FD-associated vision loss has a postnatal onset, offering a critical window for therapeutic intervention before severe visual impairment develops in adolescence. Currently, no approved treatments exist to prevent or reverse vision loss in FD. In this study, we present a novel RNA-based therapeutic approach targeting ELP1 pre-mRNA splicing in the retina. We engineered exon-specific U1 small nuclear RNAs (ExSpeU1s) to enhance inclusion of exon 20 in the mutant ELP1 transcripts in the retina, thereby restoring full-length ELP1 expression. Delivery of ExSpeU1 via adeno-associated virus serotype 2 (AAV2) to the retina improved ELP1 splicing, rescued RGC loss, and visual function in an FD mouse model. These findings highlight ExSpeU1-mediated splicing correction as a promising therapeutic approach for treating optic neuropathy in FD, offering potential to preserve vision and improve quality of life for patients.

#2

Multiple System Atrophy Combined Outcome Assessment (MuSyCA): process, format, and validation plan.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society2026 Feb 28

The Unified Multiple System Atrophy Rating Scale (UMSARS) is widely used as an outcome measure in MSA trials, but it has limitations for clinical trial use. To address these, we developed the Multiple System Atrophy Combined Outcome Assessment (MuSyCA), a comprehensive multimodal tool for disease-modifying MSA trials. The purpose of this manuscript is to describe the development and validation plan for MuSyCA, with emphasis on its structure, intended use, and assessment of reliability, validity, and sensitivity in tracking disease progression. The development of MuSyCA followed a multistep process. Candidate outcome assessments were identified through systematic literature review and analysis of longitudinal data from large MSA cohorts. Content was refined through multiple Delphi-like consensus rounds involving MSA experts, patient advocacy groups representatives, and industry stakeholders. Cognitive interviews conducted in 20  patients with MSA evaluated the clarity and clinical relevance of patient- and clinician-reported outcomes; feedback was incorporated into a subsequent version of the MuSyCA. Validation is ongoing and includes assessment of construct validity, internal consistency, test-retest reliability, and responsiveness. Longitudinal analyses to determine sensitivity to change over time are ongoing. MuSyCA combines patient- and clinician-reported outcomes, biomarkers (neurofilament light chain, neuroimaging), and performance-based measures to capture subjective and objective aspects of MSA progression, enhancing its utility  to detect treatment effects in clinical trials. MuSyCa is not intended to be used in clinical practice. MuSyCA offers a multidimensional approach to MSA assessment, supporting precise, disease-relevant evaluations in trials of putative disease-modifying therapies. Its validation will provide a standardized multimodal outcome measure, advancing MSA therapeutic development.

#3

ELP1 Gene Augmentation Restores Visual Function in a Mouse Model of Familial Dysautonomia.

bioRxiv : the preprint server for biology2026 Jan 11

Familial dysautonomia (FD) is an autosomal recessive sensory and autonomic neurodevelopmental and degenerative disorder characterized by complex neurological phenotypes. One of its most debilitating features is progressive optic neuropathy, which leads to severe visual impairment in FD patients by the third decade of life. Although several preclinical approaches have shown partial rescue of retinal ganglion cell (RGC) degeneration through increasing Elongator acetyltransferase complex subunit 1 (ELP1) expression in the retina, currently no treatments exist to prevent vision loss in FD. In this study, we performed a comprehensive analysis of visual function in a retina-specific FD mouse model ( Pax6-Cre ⁺ ;Elp1 loxp/loxp ) and evaluated a gene supplementation strategy to restore human ELP1 protein levels in the retina. Longitudinal retinal assessments indicated that FD mice exhibit significant retinal nerve fiber layer (RNFL) thinning, as observed in FD patients. FD mice also showed reduced flash visual evoked potentials (VEPs), pattern electroretinography (pERGs), and photopic negative responses (phNRs) amplitudes, along with impaired visual acuity and contrast sensitivity, as assessed using optomotor response assay (OMR). Full-field electroretinography (ffERG) revealed reduced amplitude of dark-adapted a-waves, dark and light-adapted b-waves, indicating combined RGC and bipolar cell dysfunction. Intravitreal delivery of an adeno associated vector (AAV) vector (AAV2.U1a.hELP1) effectively restored physiological ELP1 protein expression, which resulted in a significant rescue of retinal structure and function. Gene supplementation with AAV2.U1a.hELP1 resulted in broad functional and structural improvement compared with untreated FD mice. In summary, our findings provide the first demonstration that ELP1 gene supplementation can effectively rescue RGC function in an FD mouse model and support AAV2.hELP1 at an optimized dose (5.4×10 8 vg) as a promising therapeutic approach for FD-associated optic neuropathy.

#4

Establishing minimally clinically important differences for the orthostatic hypotension questionnaire (OHQ).

Clinical autonomic research : official journal of the Clinical Autonomic Research Society2026 Feb

Establish the minimally clinically important difference (MCID) for the Orthostatic Hypotension Questionnaire (OHQ). Neurogenic orthostatic hypotension (nOH) causes disabling symptoms that impair daily function and quality of life. The OHQ is a validated patient-reported outcome with a symptom assessment (OHSA) and daily activity scale (OHDAS), widely used in clinical trials, despite the MCID being unestablished. We analyzed data from two phase 3, randomized placebo-controlled trials (SEQUOIA and REDWOOD), evaluating ampreloxetine for symptomatic nOH in patients with Parkinson disease, multiple system atrophy, and pure autonomic failure. Using anchor-based and distribution-based methods, we calculated the MCID for the total OHQ score, OHSA and OHDAS composite subscales, and for the single dizziness/lightheadedness question (OHSA1). The analysis included 184 subjects from SEQUOIA and 128 from REDWOOD. The total OHQ MCID for improvement was a reduction of 0.9-1.2 points and for worsening was an increase of 0.7-1.1 points. The MCID for the OHSA composite ranged from a reduction of 0.9-1.3 points for improvement and an increase of 0.7-1.1 points for worsening. For the single-item OHSA1, the MCID was a reduction of 2.0-3.0 points for improvement and an increase of 1.0 point for worsening. Owing to poor correlation with the symptom-based anchors, a reliable MCID for the OHDAS component was not established. These MCID thresholds for the OHQ, OHSA and OHSA item 1 alone, enhance the interpretability of scores and support their use in evaluating clinical benefit.

#5

Exploratory Analysis of ELP1 Expression in Whole Blood From Patients With Familial Dysautonomia.

Annals of clinical and translational neurology2025 Dec 12

Familial dysautonomia (FD) is a hereditary neurodevelopmental disorder caused by aberrant splicing of the ELP1 gene, leading to a tissue-specific reduction in ELP1 protein expression. Preclinical models indicate that increasing ELP1 levels can mitigate disease manifestations. A blood-based ELP-1 protein assay may provide a reliable way to monitor gene target engagement. Using a newly developed radioimmunoassay, we quantified ELP1 protein levels in peripheral blood samples collected from 59 homozygous FD patients carrying the IVS20 + 6T>C mutation and 66 heterozygous carriers. To assess the reproducibility of the measurement, replicate samples were collected in 43 participants. Longitudinal variability was evaluated in 22 participants who underwent repeat sampling 1 year later. ELP1 protein levels were significantly lower in FD patients compared to heterozygous carriers (244 ± 75 vs. 2210 ± 1031 pg/mL, p < 0.001). Replicate analysis of 43 paired samples showed strong consistency in ELP1 levels (p < 0.000). Repeat measurements 1 year after baseline showed longitudinal stability (R2 = 0.827, p < 0.001). An ELP1 threshold of 492 pg/mL yielded a sensitivity of 80.2% (CI of 70.6 to 87.2%) and a specificity of 98.2% (95% CI of 90%-99%) with a positive likelihood ratio of 46.5, indicating that individuals with FD were over 46 times more likely to have ELP1 levels below this threshold compared to non-affected carriers. Blood ELP1 levels are robust and reproducible, with concentrations below 492 pg/mL strongly indicative of disease. Moreover, given their longitudinal stability, ELP1 can serve as a marker of target engagement to evaluate the efficacy of gene-targeted therapies aimed at correcting ELP1 gene splicing and protein production.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC545 artigos no totalmostrando 172

2026

Multiple System Atrophy Combined Outcome Assessment (MuSyCA): process, format, and validation plan.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society
2026

ELP1 Gene Augmentation Restores Visual Function in a Mouse Model of Familial Dysautonomia.

bioRxiv : the preprint server for biology
2026

AAV2-mediated intravitreal delivery of exon-specific U1 snRNA rescues optic neuropathy in familial dysautonomia.

Molecular therapy. Nucleic acids
2025

Exploratory Analysis of ELP1 Expression in Whole Blood From Patients With Familial Dysautonomia.

Annals of clinical and translational neurology
2025

A Rare Co-Occurrence of Gastric Heterotopia and Autonomic Nervous System Dysfunction: An Attempt to Explain If There Is a Need to Explore Possible Syndromic Link.

Journal of medical cases
2026

Establishing minimally clinically important differences for the orthostatic hypotension questionnaire (OHQ).

Clinical autonomic research : official journal of the Clinical Autonomic Research Society
2025

Peripheral neuron phenotypes of familial dysautonomia are rescued by AAV-mediated gene therapy.

Research square
2025

AAV2-mediated intravitreal delivery of exon-specific U1 snRNA rescues optic neuropathy in a mouse model of familial dysautonomia.

bioRxiv : the preprint server for biology
2025

Reproductive carrier screening for genetic disorders: position statement of the Canadian College of Medical Geneticists.

Journal of medical genetics
2025

Altered Pain Perception in a Young Adult with Childhood Trauma and Suspected Riley-Day Syndrome: A Case Report.

Reports (MDPI)
2025

Spine surgery and complication in familial dysautonomia: a case report.

Frontiers in surgery
2025

Advances in the treatment of familial dysautonomia: what does the future hold?

Expert review of neurotherapeutics
2025

Bone Mineral Density and Trabecular Bone Score in Children, Adolescents and Young Adults with Familial Dysautonomia.

Calcified tissue international
2025

Carbidopa: beyond Parkinson's disease.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society
2024

Engineered CRISPR-Base Editors as a Permanent Treatment for Familial Dysautonomia.

bioRxiv : the preprint server for biology
2024

Laminin β4 is required for the development of human peripheral sensory neurons.

bioRxiv : the preprint server for biology
2024

Genipin rescues developmental and degenerative defects in familial dysautonomia models and accelerates axon regeneration.

Science translational medicine
2025

Elp1 function in placode-derived neurons is critical for proper trigeminal ganglion development.

Developmental dynamics : an official publication of the American Association of Anatomists
2024

Atomoxetine on neurogenic orthostatic hypotension: a randomized, double-blind, placebo-controlled crossover trial.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society
2024

Neuronal and glial cell alterations involved in the retinal degeneration of the familial dysautonomia optic neuropathy.

Glia
2024

Metabolic Deficits in the Retina of a Familial Dysautonomia Mouse Model.

Metabolites
2024

ELP1, the Gene Mutated in Familial Dysautonomia, Is Required for Normal Enteric Nervous System Development and Maintenance and for Gut Epithelium Homeostasis.

The Journal of neuroscience : the official journal of the Society for Neuroscience
2024

Loss of Elp1 in cerebellar granule cell progenitors models ataxia phenotype of Familial Dysautonomia.

Neurobiology of disease
2024

Age-dependent regulation of ELP1 exon 20 splicing in Familial Dysautonomia by RNA Polymerase II kinetics and chromatin structure.

PloS one
2024

Author Correction: Transcriptome analysis in a humanized mouse model of familial dysautonomia reveals tissue-specific gene expression disruption in the peripheral nervous system.

Scientific reports
2024

Parasympathetic neurons derived from human pluripotent stem cells model human diseases and development.

Cell stem cell
2024

Retrograde tubing as a rescue treatment for megaoesophagus: a case report.

BMJ open gastroenterology
2024

Skin Biopsy Detection of Phosphorylated α-Synuclein in Patients With Synucleinopathies.

JAMA
2024

Specificity, synergy, and mechanisms of splice-modifying drugs.

Nature communications
2024

Linking the Extended Autonomic System with the Homeostat Theory: New Perspectives about Dysautonomias.

Journal of personalized medicine
2024

Transcriptome analysis in a humanized mouse model of familial dysautonomia reveals tissue-specific gene expression disruption in the peripheral nervous system.

Scientific reports
2024

The Relationship Between Scoliosis, Spinal Bone Density, and Truncal Muscle Strength in Familial Dysautonomia Patients.

Calcified tissue international
2023

Height, weight, and body mass index in patients with familial dysautonomia.

PloS one
2023

Reduction of retinal ganglion cell death in mouse models of familial dysautonomia using AAV-mediated gene therapy and splicing modulators.

Scientific reports
2023

Long-Term Outcomes of Hyperadrenergic Orthostatic Hypotension.

Research square
2023

Autonomic failure: Clinicopathologic, physiologic, and genetic aspects.

Handbook of clinical neurology
2024

Marine alkaloid rigidin analogues as potential selective inhibitors of SHP1, a new strategy for cancer immunotherapeutics.

Journal of biomolecular structure &amp; dynamics
2023

The future of rare autonomic disease research.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society
2023

Apparently rare cases are worth studying because….

Clinical autonomic research : official journal of the Clinical Autonomic Research Society
2024

Sensorimotor control in the congenital absence of functional muscle spindles.

Experimental physiology
2023

Genipin Crosslinks the Extracellular Matrix to Rescue Developmental and Degenerative Defects, and Accelerates Regeneration of Peripheral Neurons.

bioRxiv : the preprint server for biology
2023

A Comprehensive NMR Analysis of Serum and Fecal Metabolites in Familial Dysautonomia Patients Reveals Significant Metabolic Perturbations.

Metabolites
2023

A novel ELP1 mutation impairs the function of the Elongator complex and causes a severe neurodevelopmental phenotype.

Journal of human genetics
2023

Development of an oral treatment that rescues gait ataxia and retinal degeneration in a phenotypic mouse model of familial dysautonomia.

American journal of human genetics
2023

Gastrointestinal bleeding in children with familial dysautonomia: a case-control study.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society
2023

Gut microbiome dysbiosis drives metabolic dysfunction in Familial dysautonomia.

Nature communications
2022

Norepinephrine transporter defects lead to sympathetic hyperactivity in Familial Dysautonomia models.

Nature communications
2022

Elongator promotes neuritogenesis via regulation of tau stability through acly activity.

Frontiers in cell and developmental biology
2022

Experience With Dexmedetomidine Use in the Treatment of Dysautonomic Crisis in Familial Dysautonomia: An Off-Label Use.

Cureus
2022

Counter pressure maneuvers for syncope prevention: A semi-systematic review and meta-analysis.

Frontiers in cardiovascular medicine
2022

Jaw-in-a-Riley-Day: Mandibular Free Flap Reconstruction With Virtual Surgical Planning in a Patient With Familial Dysautonomia.

Cureus
2022

Rescue of a familial dysautonomia mouse model by AAV9-Exon-specific U1 snRNA.

American journal of human genetics
2022

Diagnosis and treatment of orthostatic hypotension.

The Lancet. Neurology
2022

Commentary: Congenital corneal anesthesia: A rare form of type-4 familial dysautonomia.

Indian journal of ophthalmology
2022

Engineered U1 snRNAs to modulate alternatively spliced exons.

Methods (San Diego, Calif.)
2022

Loss of Elp1 disrupts trigeminal ganglion neurodevelopment in a model of familial dysautonomia.

eLife
2022

Carnosol, a diterpene present in rosemary, increases ELP1 levels in familial dysautonomia patient-derived cells and healthy adults: a possible therapy for FD.

Human molecular genetics
2022

A Closer Look at Familial Dysautonomia from a Social Communication Perspective: A Case Report and Review of Literature.

Psychiatry and clinical psychopharmacology
2022

AAMR syndrome in a 22-month-old and literature review.

Ophthalmic genetics
2022

Elp1 is required for development of visceral sensory peripheral and central circuitry.

Disease models &amp; mechanisms
2022

Neuropathic-like Pain in Fibrous Dysplasia/McCune-Albright Syndrome.

The Journal of clinical endocrinology and metabolism
2022

Selective retinal ganglion cell loss and optic neuropathy in a humanized mouse model of familial dysautonomia.

Human molecular genetics
2022

Developmental regulation of neuronal gene expression by Elongator complex protein 1 dosage.

Journal of genetics and genomics = Yi chuan xue bao
2021

Author Correction: Therapeutic manipulation of IKBKAP mis-splicing with a small molecule to cure familial dysautonomia.

Nature communications
2021

ATP-citrate lyase promotes axonal transport across species.

Nature communications
2021

Loss of Elp1 perturbs histone H2A.Z and the Notch signaling pathway.

Biology open
2021

Induced pluripotent stem cell (iPSC) lines from two individuals carrying a homozygous (BGUi007-A) and a heterozygous (BGUi006-A) mutation in ELP1 for in vitro modeling of familial dysautonomia.

Stem cell research
2021

Therapeutic manipulation of IKBKAP mis-splicing with a small molecule to cure familial dysautonomia.

Nature communications
2021

The case of a patient with MIRAGE syndrome with familial dysautonomia-like symptoms.

Human genome variation
2022

Uncommon side effects of common drugs in patients with familial dysautonomia.

Pharmacoepidemiology and drug safety
2021

Recurrent abdominal pain in hereditary sensory autonomic neuropathy type II (HSAN-II).

Revue neurologique
2021

A deep learning approach to identify gene targets of a therapeutic for human splicing disorders.

Nature communications
2021

Bone biomechanical properties and tissue-scale bone quality in a genetic mouse model of familial dysautonomia.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
2021

Fludrocortisone for orthostatic hypotension.

The Cochrane database of systematic reviews
2021

Limitations of the Unified Multiple System Atrophy Rating Scale as outcome measure for clinical trials and a roadmap for improvement.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society
2021

Derivation of Peripheral Nociceptive, Mechanoreceptive, and Proprioceptive Sensory Neurons from the same Culture of Human Pluripotent Stem Cells.

Stem cell reports
2021

Retrograde nerve growth factor signaling abnormalities and the pathogenesis of familial dysautonomia.

Neural regeneration research
2021

Cytoprotective activities of kinetin purine isosteres.

Bioorganic &amp; medicinal chemistry
2021

Longitudinal changes in the macula and optic nerve in familial dysautonomia.

Journal of neurology
2020

Genetically Established Familial Amyloidotic Polyneuropathy from India: Narrating the Diagnostic "Odyssey" and a Mini Review.

Neurology India
2021

Frequency and burden of gastrointestinal symptoms in familial dysautonomia.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society
2020

Von Economo Neuron Pathology in Familial Dysautonomia: Quantitative Assessment and Possible Implications.

Journal of neuropathology and experimental neurology
2021

Clinical and confocal imaging findings in congenital corneal anaesthesia.

The British journal of ophthalmology
2020

Development of the Autonomic Nervous System: Clinical Implications.

Seminars in neurology
2020

Afferent Baroreflex Dysfunction: Decreased or Excessive Signaling Results in Distinct Phenotypes.

Seminars in neurology
2020

Acute Sensory and Autonomic Neuronopathy: A Devastating Disorder Affecting Sensory and Autonomic Ganglia.

Seminars in neurology
2020

Carbidopa for Afferent Baroreflex Failure in Familial Dysautonomia: A Double-Blind Randomized Crossover Clinical Trial.

Hypertension (Dallas, Tex. : 1979)
2020

The impact of supine hypertension on target organ damage and survival in patients with synucleinopathies and neurogenic orthostatic hypotension.

Parkinsonism &amp; related disorders
2020

Elbow proprioception is normal in patients with a congenital absence of functional muscle spindles.

The Journal of physiology
2020

Retrograde nerve growth factor signaling abnormalities in familial dysautonomia.

The Journal of clinical investigation
2020

(H)Elping nerve growth factor: Elp1 inhibits TrkA's phosphatase to maintain retrograde signaling.

The Journal of clinical investigation
2020

Impact of a national genetic carrier-screening program for reproductive purposes.

Acta obstetricia et gynecologica Scandinavica
2019

Hereditary Sensory and Autonomic Neuropathies: Adding More to the Classification.

Current neurology and neuroscience reports
2019

Generation of Neural Crest Progenitors from Human Pluripotent Stem Cells.

Methods in molecular biology (Clifton, N.J.)
2019

ELP1 Splicing Correction Reverses Proprioceptive Sensory Loss in Familial Dysautonomia.

American journal of human genetics
2019

Chemoreflex failure and sleep-disordered breathing in familial dysautonomia: Implications for sudden death during sleep.

Autonomic neuroscience : basic &amp; clinical
2019

Combinatorial treatment increases IKAP levels in human cells generated from Familial Dysautonomia patients.

PloS one
2019

Quantitative magnetic resonance evaluation of the trigeminal nerve in familial dysautonomia.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society
2018

Patient-Derived Induced Pluripotent Stem Cells for Alpha-1 Antitrypsin Deficiency Disease Modeling and Therapeutic Discovery.

Chronic obstructive pulmonary diseases (Miami, Fla.)
2019

Autonomic Neurons with Sympathetic Character Derived From Human Pluripotent Stem Cells.

Current protocols in stem cell biology
2019

Improvement of daytime hypercapnia with nocturnal non-invasive ventilation in familial dysautonomia.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society
2019

Induced pluripotent stem cells for disease modeling, cell therapy and drug discovery in genetic autonomic disorders: a review.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society
2019

Long-term outcome of using Prosthetic Replacement of Ocular Surface Ecosystem (PROSE) as a drug delivery system for bevacizumab in the treatment of corneal neovascularization.

The ocular surface
2019

Resting Energy Expenditure in Patients With Familial Dysautonomia: A Preliminary Study.

Journal of pediatric gastroenterology and nutrition
2019

Development of a Screening Platform to Identify Small Molecules That Modify ELP1 Pre-mRNA Splicing in Familial Dysautonomia.

SLAS discovery : advancing life sciences R &amp; D
2018

Case Series: Management of Neurotrophic Keratitis from Familial Dysautonomia.

Optometry and vision science : official publication of the American Academy of Optometry
2018

Respiratory care in familial dysautonomia: Systematic review and expert consensus recommendations.

Respiratory medicine
2018

Retina-specific loss of Ikbkap/Elp1 causes mitochondrial dysfunction that leads to selective retinal ganglion cell degeneration in a mouse model of familial dysautonomia.

Disease models &amp; mechanisms
2018

Orthostatic hypotension: does the heart rate matter? And other updates on recent autonomic research.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society
2018

Blocking of an intronic splicing silencer completely rescues IKBKAP exon 20 splicing in familial dysautonomia patient cells.

Nucleic acids research
2018

Exon-specific U1 snRNAs improve ELP1 exon 20 definition and rescue ELP1 protein expression in a familial dysautonomia mouse model.

Human molecular genetics
2018

Characteristics of ataxic gait in familial dysautonomia patients.

PloS one
2018

Prevalence and characteristics of sleep-disordered breathing in familial dysautonomia.

Sleep medicine
2018

Antisense oligonucleotides correct the familial dysautonomia splicing defect in IKBKAP transgenic mice.

Nucleic acids research
2018

Female-Specific Association Between Variants on Chromosome 9 and Self-Reported Diagnosis of Irritable Bowel Syndrome.

Gastroenterology
2018

Identification of neuronal autophagy regulators: Combined use of iKAP and THANATOS.

Movement disorders : official journal of the Movement Disorder Society
2018

Improvement of chronic corneal opacity in ocular surface disease with prosthetic replacement of the ocular surface ecosystem (PROSE) treatment.

American journal of ophthalmology case reports
2018

Elongator complex is required for long-term olfactory memory formation in Drosophila.

Learning &amp; memory (Cold Spring Harbor, N.Y.)
2018

Elongator and codon bias regulate protein levels in mammalian peripheral neurons.

Nature communications
2018

Ambulatory blood pressure profiles in familial dysautonomia.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society
2018

Structural insights into the function of Elongator.

Cellular and molecular life sciences : CMLS
2017

IKBKAP/ELP1 gene mutations: mechanisms of familial dysautonomia and gene-targeting therapies.

The application of clinical genetics
2018

Founder mutation in IKBKAP gene causes vestibular impairment in familial dysautonomia.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
2018

A Controlled Trial of Inhaled Bronchodilators in Familial Dysautonomia.

Lung
2018

Neurogenic dysphagia with undigested macaroni and megaesophagus in familial dysautonomia.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society
2017

Basic research and model systems in familial dysautonomia: What do we know and what's next?

Clinical autonomic research : official journal of the Clinical Autonomic Research Society
2017

Intranasal dexmedetomidine for adrenergic crisis in familial dysautonomia.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society
2017

Animal and cellular models of familial dysautonomia.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society
2017

RBM24 promotes U1 snRNP recognition of the mutated 5' splice site in the IKBKAP gene of familial dysautonomia.

RNA (New York, N.Y.)
2017

Phosphatidylserine improves axonal transport by inhibition of HDAC and has potential in treatment of neurodegenerative diseases.

Neural regeneration research
2016

[ORO-DENTO-FACIAL MANIFESTATIONS IN PATIENTS WITH FAMILIAL DYSAUTONOMIA].

Harefuah
2017

Sudden Unexpected Death During Sleep in Familial Dysautonomia: A Case-Control Study.

Sleep
2017

BGP-15 prevents the death of neurons in a mouse model of familial dysautonomia.

Proceedings of the National Academy of Sciences of the United States of America
2017

Proteasome inhibitors to alleviate aberrant IKBKAP mRNA splicing and low IKAP/hELP1 synthesis in familial dysautonomia.

Neurobiology of disease
2017

Familial dysautonomia: a disease with hidden tears.

Journal of neurology
2017

Pathological Confirmation of Optic Neuropathy in Familial Dysautonomia.

Journal of neuropathology and experimental neurology
2017

Modulation of aberrant splicing in human RNA diseases by chemical compounds.

Human genetics
2017

The familial dysautonomia disease gene IKBKAP is required in the developing and adult mouse central nervous system.

Disease models &amp; mechanisms
2018

Genetic Polymorphisms in the ESR1 and VDR Genes Do Not Correlate With Osteoporosis in Patients With Familial Dysautonomia.

Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry
2017

Caring for adolescents with familial dysautonomia.

Nursing
2016

Phosphatidylserine Ameliorates Neurodegenerative Symptoms and Enhances Axonal Transport in a Mouse Model of Familial Dysautonomia.

PLoS genetics
2017

Unusual Structural Autonomic Disorders Presenting in Pediatrics: Disorders Associated with Hypoventilation and Autonomic Neuropathies.

Pediatric clinics of North America
2016

Sleep Apnea in Familial Dysautonomia: A Reflection of Apnea Pathogenesis.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
2016

The Many Faces of Elongator in Neurodevelopment and Disease.

Frontiers in molecular neuroscience
2016

Capturing the biology of disease severity in a PSC-based model of familial dysautonomia.

Nature medicine
2017

Dexmedetomidine for refractory adrenergic crisis in familial dysautonomia.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society
2016

Loss of Ikbkap Causes Slow, Progressive Retinal Degeneration in a Mouse Model of Familial Dysautonomia.

eNeuro
2016

Poster 72 Teetering on the Edge: Rehabilitation in a Medically Complex Patient with Familial Dysautonomia (Hereditary Sensory Autonomic Neuropathy Type III): A Case Report.

PM &amp; R : the journal of injury, function, and rehabilitation
2016

Obstructive Sleep-Disordered Breathing Is More Common than Central in Mild Familial Dysautonomia.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
2016

Opinion commune de la SOGC et du CCGM sur le dépistage génétique en contexte de procréation : Mise à jour à l'intention de l'ensemble des prestataires canadiens de soins de santé maternelle et de services en procréation, à l'ère des tests offerts directement aux consommateurs.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC
2016

Joint SOGC-CCMG Opinion for Reproductive Genetic Carrier Screening: An Update for All Canadian Providers of Maternity and Reproductive Healthcare in the Era of Direct-to-Consumer Testing.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC
2017

Cerebral autoregulation and symptoms of orthostatic hypotension in familial dysautonomia.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
2016

Familial Dysautonomia: Mechanisms and Models.

Genetics and molecular biology
2016

Intestinal ischemia in neonates and children.

Clujul medical (1957)
2016

MicroRNA screening identifies a link between NOVA1 expression and a low level of IKAP in familial dysautonomia.

Disease models &amp; mechanisms
2016

[The function of autonomic nervous system during paroxysmal events in children and adolescents, and available diagnostic methods].

Przeglad lekarski
2017

Familial dysautonomia: History, genotype, phenotype and translational research.

Progress in neurobiology
2016

Tocotrienol Treatment in Familial Dysautonomia: Open-Label Pilot Study.

Journal of molecular neuroscience : MN
2016

Sensory and autonomic deficits in a new humanized mouse model of familial dysautonomia.

Human molecular genetics
2016

Phosphatidylserine enhances IKBKAP transcription by activating the MAPK/ERK signaling pathway.

Human molecular genetics
2016

Axon Transport and Neuropathy: Relevant Perspectives on the Etiopathogenesis of Familial Dysautonomia.

The American journal of pathology
2016

Increasing cutaneous afferent feedback improves proprioceptive accuracy at the knee in patients with sensory ataxia.

Journal of neurophysiology
2016

Mother-induced hypertension in familial dysautonomia.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society
2016

TECPR2 mutations cause a new subtype of familial dysautonomia like hereditary sensory autonomic neuropathy with intellectual disability.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
2016

Brainstem reflexes in familial dysautonomia. Reply to "Evidence of brainstem dysfunction in patients with familial dysautonomia and carriers of the IKBKAP mutation".

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
2016

Evidence of brainstem dysfunction in patients with familial dysautonomia and carriers of the IKBKAP mutation.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
2015

Familial Dysautonomia (FD) Human Embryonic Stem Cell Derived PNS Neurons Reveal that Synaptic Vesicular and Neuronal Transport Genes Are Directly or Indirectly Affected by IKBKAP Downregulation.

PloS one
2015

Chewing-induced hypertension in afferent baroreflex failure: a sympathetic response?

Experimental physiology
2015

Dimerization of elongator protein 1 is essential for Elongator complex assembly.

Proceedings of the National Academy of Sciences of the United States of America
2015

Increased frequency of rhabdomyolysis in familial dysautonomia.

Muscle &amp; nerve
2015

Contemporary perioperative management of adult familial dysautonomia (Riley-Day syndrome).

A &amp; A case reports
2015

Rectifier of aberrant mRNA splicing recovers tRNA modification in familial dysautonomia.

Proceedings of the National Academy of Sciences of the United States of America
Ver todos os 545 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Disautonomia familiar.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Disautonomia familiar

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. AAV2-mediated intravitreal delivery of exon-specific U1 snRNA rescues optic neuropathy in familial dysautonomia.
    Molecular therapy. Nucleic acids· 2026· PMID 41536810mais citado
  2. Multiple System Atrophy Combined Outcome Assessment (MuSyCA): process, format, and validation plan.
    Clinical autonomic research : official journal of the Clinical Autonomic Research Society· 2026· PMID 41762390mais citado
  3. ELP1 Gene Augmentation Restores Visual Function in a Mouse Model of Familial Dysautonomia.
    bioRxiv : the preprint server for biology· 2026· PMID 41542655mais citado
  4. Establishing minimally clinically important differences for the orthostatic hypotension questionnaire (OHQ).
    Clinical autonomic research : official journal of the Clinical Autonomic Research Society· 2026· PMID 41134458mais citado
  5. Exploratory Analysis of ELP1 Expression in Whole Blood From Patients With Familial Dysautonomia.
    Annals of clinical and translational neurology· 2025· PMID 41385477mais citado
  6. Prime editing of the common Familial Dysautonomia-causing c.2204 + 6T > C splicing mutation.
    Orphanet J Rare Dis· 2026· PMID 41964038recente
  7. Peripheral neuron phenotypes of familial dysautonomia are rescued by AAV-mediated gene therapy.
    Clin Auton Res· 2026· PMID 41957238recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:1764(Orphanet)
  2. OMIM OMIM:223900(OMIM)
  3. MONDO:0009131(MONDO)
  4. GARD:7581(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Artigo Wikipedia(Wikipedia)
  8. Q2325854(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Disautonomia familiar
Compêndio · Raras BR

Disautonomia familiar

ORPHA:1764 · MONDO:0009131
Prevalência
<1 / 1 000 000
Herança
Autosomal recessive
CID-10
G90.1 · Disautonomia familiar [Síndrome de Riley-Day]
CID-11
Ensaios
3 ativos
Medicamentos
2 registrados
Início
Childhood, Infancy, Neonatal
Prevalência
0.0 (Europe)
MedGen
UMLS
C0013364
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades